A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: A follow-up analysis

Medical Science Monitor

Volumn 11, Issue 4, 2005, Pages

  Geier, David A ^a   Geier, Mark R ^b,c  

^a MedCon Inc   (United States)

^b Genetic Centers of America   (United States)

^c NONE   (United States)

Author keywords

Mercury; Merthiolate; Thimerasol; Thiomersal; VAERS; VSD

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DRUG PRESERVATIVE; ETHYLMERCURY DERIVATIVE; THIOMERSAL; VACCINE;

ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; CLINICAL TRIAL; COMPULSION; DEVELOPMENTAL DISORDER; DRUG SAFETY; EATING DISORDER; EMOTIONAL DISORDER; ENURESIS; FEMALE; FOLLOW UP; HUMAN; INFANT; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; NEUROLOGIC DISEASE; PERSONALITY DISORDER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PSYCHOSIS; RISK FACTOR; SLEEP DISORDER; SPEECH DISORDER; THOUGHT DISORDER; TIC;

CHILD; DATABASES, FACTUAL; DIPHTHERIA TOXOID; FEMALE; FEVER; HUMANS; MALE; PATIENT SELECTION; PERTUSSIS TOXIN; SEIZURES; THIMEROSAL; VACCINES;

EID: 17444424266     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Blaxill MF: What's going on? The question of time trends in autism. Public Health Rep, 2004; 119: 536-51
2. Gerlai R, Gerlai J: Autism: a for pharmacotherapies? Drug Discov Today, 2004; 9: 366-74
3. Gerlai R, Gerlai J: Autism: a large unmet medical need and a complex research problem. Physiol Behav, 2003; 79: 461-70
4. Bertrand J, Mars A, Boyle C et al: Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics, 2001; 108: 1155-61
5. Yeargin-Allsopp M, Rice C, Karapurkar T et al: Prevalence of autism in a US metropolitan area. JAMA, 2003; 289: 49-55
6. California Department of Developmental Services: Autistic Spectrum Disorders - Changes in the California Caseload - An Update: 1999 through 2002. Sacramento, CA: State of California, 2003
7. Blaxill MF, Baskin DS, Spitzer WO: Commentary: Blaxill, Baskin, and Spitzer on Croen et al: (2002), the changing prevalence of autism in California. J Autism Dev Disord, 2003; 33: 223-26
8. Ball LK, Ball R, Pratt RD: An assessment of thimerosal use in childhood vaccines. Pediatrics, 2001; 107: 1147-54
9. Redwood L, Bernard S, Brown D: Predicted mercury concentrations in hair from infant immunizations: cause for concern. Neurotoxicology, 2001; 22: 691-97
10. Bernard S, Enayati A, Redwood L et al: Autism: a novel form of mercury poisoning. Med Hypotheses, 2001; 56: 462-71
11. Bernard S, Enayati A, Roger H et al: The role of mercury in the pathogenesis of autism. Mol Psychiatry, 2002; 7(Suppl.2): S42-43
12. Blaxill MF, Redwood L, Bernard S: Thimerosal and autism? A plausible hypothesis that should not be dismissed. Med Hypotheses, 2004; 62: 788-94
13. Geier DA, Geier MR: A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism. Med Sci Monit, 2004; 10(3): PI33-39
14. Singleton JA, Lloyd JC, Mootrey GT et al: An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group. Vaccine, 1999; 17: 2908-17
15. Rosenthal S, Chen R, Hadler S: The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med, 1996; 150: 457-60
16. rd edition. New York: W.B. Saunders Company, 1999
17. Chen RT, Glasser JW, Rhodes PH et al: Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics, 1997; 99: 765-73
18. Barlow WE, Davis RL, Glasser JW et al: The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med, 2001; 345: 656-61
19. Mullooly J, Drew L, DeStefano F et al: Quality of HMO vaccination databases used to monitor childhood vaccine safety. Vaccine Safety DataLink Team. Am J Epidemiol, 1999; 149: 186-94
20. Lloyd JC, Haber P, Mootrey GT et al: Adverse event reporting rates following tetanus-diphtheria and tetanus toxoid vaccinations: data from the Vaccine Adverse Event Reporting System (VAERS). 1991-1997. Vaccine, 2003; 21: 3746-50
21. Chen R, Rosenthal S: An errant critique that misses the mark. Arch Pediatr Adolesc Med, 1996; 150: 464-45
22. Geier DA, Geier MR: A review of the Vaccine Adverse Event Reporting System database. Expert Opin Pharmacother, 2004; 5: 691-98
23. Verstraeten T, DeStefano F, Chen RT et al: Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines. Expert Rev Vaccines, 2003; 2: 21-29
24. Stehr-Green P, Tull P, Stellfeld M, Mortenson PB, Simpson D: Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med, 2003; 25: 101-6
25. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M: Association between thimerosal-containing vaccine and autism. JAMA, 2003; 290: 1763-76
26. Madsen KM, Lauritsen MB, Pedersen CB et al: Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics, 2003; 112: 604-6
27. Andrews N, Miller E, Grant A et al: Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association. Pediatrics, 2004; 114: 584-91
28. Heron J, Golding J; ALSPAC Study Team: Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association. Pediatrics, 2004; 114: 577-83
29. Verstraeten T, Davis RL, DeStefano F et al: Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics, 2003; 112: 1039-48
30. Verstraeten T: Thimerosal, the Centers for Disease Control and Prevention, and GlaxoSmithKline. Pediatrics, 2004; 113: 932
31. Geier MR, Geier DA: Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med, 2003; 228: 660-64
32. Geier MR, Geier DA: Thimerosal in childhood vaccines, neurodevelopment disorders, and heart disease in the United States. J Am Phys Surg, 2003; 8: 6-11
33. Geier DA, Geier MR: An assessment of the impact of thimerosal on neurodevelopmental disorders. Pediatr Rehabil, 2003; 6: 97-102
34. Geier DA, Geier MR: Neurodevelopmental disorders following thimerosal-containing childhood immunizations: a follow-up analysis. Int J Toxicol, (in press).
35. Bradstreet J, Geier DA, Kartzinel JJ: A case-control study of mercury burden in children with autistic spectrum disorders. J Am Physicians Surg, 2003; 8: 76-79
36. Holmes AS, Blaxill MF, Haley BE: Reduced levels of mercury in first baby haircuts of autistic children. Int J Toxicol, 2003; 22: 277-85
37. James SJ: Increased oxidative stress and impaired methylation capacity in children with autism: metabolic biomarkers and genetic predisposition. Fall DAN!™ 2004 Conference, Los Angles, CA, 1-3 October, 2004; 143-59
38. James SJ, Culter P, Melnyk S et al: Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr, 2004, 80: 1611-17
39. Boris M, Goldblatt A, Galanko J, James SJ: Association of 5,10-Methyle netetrathydrofolate reductase (MTHFR) gene polymorphisms with autistic spectrum disorders. J Am Phys Surg, (in press)
40. Gasset AR, Itoi M, Ishii Y, Ramer RM: Teratogenicities of ophthalmic drugs. II. Teratogenicities and tissue accumulation of thimerosal. Arch Ophthalmol, 1975; 93: 52-55
41. Slikker W: Developmental neurotoxicology of therapeutics: survey of novel recent findings. Neurotoxicology, 2000; 21: 250
42. Institute of Medicine (US): Immunization Safety Review: Vaccines and Autism. Washington, DC: National Academy Press, 2004
43. Baskin DS, Ngo H, Didenko VV: Thimerosal induces DNA breaks, caspase-3 activation, membrane damage, and cell death in cultured human neurons and fibroblasts. Toxicol Sci, 2003; 74: 361-68
44. Leong CWC, Syed NI, Lorscheider FL: Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following in vitro exposure to mercury. NeuroReport, 2001; 12: 733-37
45. Parry JM: An evaluation of the use of in vitro tubulin polymerisation, fungal and wheat assays to detect the activity of potential chemical aneugens. Mutation Res, 1993; 287: 23-28
46. Wallin M, Hartely-Asp B: Effects of potential aneuploidy inducing agents on microtubule assembly in vitro. Mutation Res, 1993; 287: 17-22
47. Brunner M, Albertini S, Wurgler FE: Effects of 10 known or suspected spindle poisons in the in vitro porcine brain tubulin assembly assay. Mutagenesis, 1991; 6: 65-70
48. James SJ, Slikker W 3rd, Melnyk S et al: Thimerosal neurotoxicity is associated with glutathione depletion: protection with glutathione precursors. Neurotoxicology, 2005; 26: 1-8
49. Waly M, Olteanu H, Banerjee R et al: Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and Thimerosal. Mol Psychiatry, 2004; 9: 358-70
50. Deth RC, Waly M: How genetic risks combine with Thimerosal to inhibit methionine synthase and cause autism. Fall DAN!™ 2004 Conference, Los Angles, California, 1-3 October 2004, pgs. 161-74
51. Hornig M, Chian D, Lipkin WI: Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Mol Psychiatry, 2004; 9: 833-45
52. Clarkson TW, Nordberg FJ, Sager PR: Reproductive and developmental toxicity of metals. Scand J Work Environ Health, 1985; 11: 145-54
53. Grandjean P, Weihe P, White RF, Debes F: Cognitive performance of children prenatally exposed to "safe" levels of methylmercury. Environ Res, 1998; 77: 165-72
54. Geier MR, Geier DA: The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypothesis, (in press)
55. Environmental Working Group: Overloaded? New Science, New Insights about Mercury and Autism in Susceptible Children. Washington, DC: EWG Action Fund; 2004